Metraipolis › archive › dc_5b438daf7cf5

The impact of metabolic dysfunction-associated steatotic liver disease on the efficacy of pegylated interferon-based therapy in patients with chronic… — Europe PMC PMID:41583459

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41583459
DOI
10.3389/fimmu.2025.1708909
License (as archived)
solo-consultazione
Archived
2026-11-06T22:59:56.989Z
SHA-256 of the archived text
dfad6d8ff5981ceaed7d555bad5a78ca7cc3f47370a65d5c40e6f0eb3a76fd1a
Stable URL of this page
https://metraipolis.com/documento/dc_5b438daf7cf5

How to cite

The impact of metabolic dysfunction-associated steatotic liver disease on the efficacy of pegylated interferon-based therapy in patients with chronic… — Europe PMC PMID:41583459 — Europe PMC (en), https://europepmc.org/article/MED/41583459 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_5b438daf7cf5 (Metraipolis archive dc_5b438daf7cf5, sha256 dfad6d8ff5981ceaed7d555bad5a78ca7cc3f47370a65d5c40e6f0eb3a76fd1a)
BibTeX
@misc{dc5b438daf7cf5,
  title = {The impact of metabolic dysfunction-associated steatotic liver disease on the efficacy of pegylated interferon-based therapy in patients with chronic… — Europe PMC PMID:41583459},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41583459},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_5b438daf7cf5; sha256 dfad6d8ff5981ceaed7d555bad5a78ca7cc3f47370a65d5c40e6f0eb3a76fd1a},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41583459. Agents can read the archived copy with the MCP tool read_document.